Vitamin D Supplementation Clinical Trial
Official title:
Clinical Trial of Vitamin D Supplementation in Healthy Adolescents
NCT number | NCT01126671 |
Other study ID # | 08-06-0271 |
Secondary ID | |
Status | Completed |
Phase | N/A |
First received | |
Last updated | |
Start date | November 2008 |
Est. completion date | June 2011 |
Verified date | May 2018 |
Source | Boston Children’s Hospital |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This double blind, randomized controlled trial compares two supplemental doses of vitamin D in health adolescents.
Status | Completed |
Enrollment | 56 |
Est. completion date | June 2011 |
Est. primary completion date | June 2011 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 11 Years to 18 Years |
Eligibility |
Inclusion Criteria: - 11-18 years old - healthy Exclusion Criteria: - chronic disease - use of medication known to effect bone or vitamin D metabolism - abnormal vitamin D or calcium at screening - pregnant - body mass index <5% or >95% |
Country | Name | City | State |
---|---|---|---|
United States | Children's Hospital Boston | Boston | Massachusetts |
Lead Sponsor | Collaborator |
---|---|
Boston Children’s Hospital |
United States,
Putman MS, Pitts SA, Milliren CE, Feldman HA, Reinold K, Gordon CM. A randomized clinical trial of vitamin D supplementation in healthy adolescents. J Adolesc Health. 2013 May;52(5):592-8. doi: 10.1016/j.jadohealth.2012.10.270. Epub 2012 Dec 23. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Baseline 25 Hydroxy Vitamin D (25OHD) Levels | 25OHD will be drawn at baseline prior to starting vitamin D supplementation. | Baseline | |
Primary | Follow-up 25OHD Levels | After 11weeks of treatment, repeat 25OHD levels will be drawn to assess subject response to vitamin D supplementation. | 12 weeks | |
Secondary | Baseline Assessment of Bone Markers | Bone specific alkaline phosphatase, CTx, and osteocalcin will be assessed at baseline prior to subjects starting vitamin D supplementation | Baseline | |
Secondary | Assessment of Bone Markers at Follow-up | After 11 weeks of vitamin D supplementation bone specific alkaline phosphatase, osteocalcin, and CTx will be repeated to see response to therapy. | 12 weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06098846 -
Human Transdermal Vitamin D Supplement Study
|
N/A | |
Not yet recruiting |
NCT05616117 -
Next-generation Effects of Vitamin D Supplementation in Pregnancy
|
||
Recruiting |
NCT04025489 -
Vitamin D Supplementation on Surrogate Markers of Ageing, Ageing Genes, Glycemic and Metabolic Markers in North India
|
N/A | |
Completed |
NCT04121533 -
Vitamin D Supplementation in Knee Osteoarthritis
|
N/A | |
Completed |
NCT03437421 -
Myocardial Function and Vitamin D Supplementation in Diabetes.
|
N/A | |
Not yet recruiting |
NCT02002000 -
Chronic Pain and Vitamin D
|
N/A | |
Completed |
NCT05867784 -
Effect of Vitamin D Supplementation on the Efficacy of Ustekinumab in the Treatment of Crohn's Disease
|